No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GRAL Grail
- 20.780
- +1.330+6.84%
Trading Jul 17 14:08 ET
645.27MMarket Cap-432P/E (TTM)
21.470High18.875Low1.86MVolume19.440Open19.450Pre Close38.70MTurnover6.00%Turnover RatioLossP/E (Static)31.05MShares23.36052wk High0.17P/B645.27MFloat Cap12.51052wk Low--Dividend TTM31.05MShs Float23.360Historical High--Div YieldTTM13.34%Amplitude12.510Historical Low20.771Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Dow, S&P 500 Hit Closing Records as Markets Weigh Retail Sales Report, Earnings
The Dow Jones Industrial Average and the S&P 500 closed at all-time highs Tuesday as markets assessed official retail sales data for June and the latest corporate earnings.The Dow jumped 1.9% to 40,95
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test.
Express News | GRAIL Shares Are Trading Higher After the Company Provided an Update on the PATHFINDER 2 and NHS-Galleri Registrational Clinical Trials Evaluating the Galleri Multi-cancer Early Detection Test
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Health care stocks were edging higher premarket Monday with the Health Care Select Sector SPDR Fund (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) recently advancing by 0.4%.ASLAN
The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea -- WSJ
Whether millions of people will be able to afford one of the hot new weight-loss drugs could hinge on whether they cure the sleep apnea of people like Damon Sedgwick.
Grail Completes Enrollment in US Study for Cancer Early-Detection Device
Grail Inc. (GRAL) said Monday it has completed the enrollment of more than 35,000 people for its US study of Galleri, the company's potential multi-cancer early detection test, at more than 30
Comments
$Grail(GRAL.US$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina(ILMN.US$ botched the acquisition of $Grail(GRAL.US$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail(GRAL.US$ why circuit breaker?
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
